One of the most challenging issues for pharmaceutical manufacturers has been putting effective processes and tools in place to manage contract eligibility.

Offering the 340B price to a non-eligible entity can lead to:

  • Inaccurate computation of Best Price
  • Incorrect reporting of AMP and BP data
  • Incorrect payments of Medicaid rebates to states
  • Incorrect reporting to the VA of Non-FAMP data
  • Severe revenue loss or fines

Alliance Life Sciences’ PHS eligibility solution protects against these violations

To Download the Service Offering, Click Here.